Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790736 · ClinicalTrials.gov registry record · Phase 4
Brief Intervention to Reduce Fear of Public Speaking
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT02790736: Clinical Trial Phase 4 study, sponsored by New York State Psychiatric Institute.
NCT02790736 is a Phase 4 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02790736, a Phase 4 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.
Primary Outcome
total score on this self report measure of fear of public speaking. Scored from 0-30, with higher scores indicating better outcome
Interventions
- DRUG Placebo
- DRUG propranolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 4 |
Why NCT02790736 stopped before completion
NCT02790736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02790736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02790736 about?
NCT02790736 is a clinical study titled "Brief Intervention to Reduce Fear of Public Speaking". The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.
What is the current status of trial NCT02790736?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2016-06. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT02790736?
The interventions under investigation include: Placebo (DRUG), propranolol (DRUG).
Who is sponsoring clinical trial NCT02790736?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02790736's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia